A Prospective and Retrospective Cohort Study in Patients With Chronic Forms of Acid Sphingomyelinase Deficiency (ASMD)

Completed · Not applicable

Conditions studied: Sphingomyelin Lipidosis

In brief

Primary Objective: * To describe the clinical features and their severity at the time of diagnosis and their evolution over time in patients with confirmed chronic visceral and chronic neurovisceral forms of ASMD * To describe Clinician-Reported Outcomes (ClinROs) and Patient-Reported Outcomes (PROs) at enrollment and their evolution over time; disease severity at the time of diagnosis and its evolution over time Secondary Objectives: * To describe abnormal values in laboratory parameters and all values of specific clinical and imaging assessments at the time of diagnosis and their evolution over time * To study the use and applicability towards validation of a newly developed ASMD disease severity scoring system * To study the use and applicability towards validation of a newly developed ASMD PRO tool * To describe ASMD-related disease burden among patients with ASMD, caregivers, and healthcare resource utilization * To describe the association between patient demographics (eg, age, gender, race, Ashkenazi ancestry) and genotype with selected clinical features in patients with confirmed chronic visceral and chronic neurovisceral forms of ASMD

Key facts

Study ID

NCT04106544

Run by

Sanofi

People needed

84

Starts

2019-09-27

Expected to finish

2023-05-15

Last updated by the study team

2023-08-16

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients with confirmed diagnosis of chronic forms of ASMD based on 1) a clinical diagnosis consistent with chronic visceral ASMD (ie, NPD B) or chronic neurovisceral ASMD (ie, NPD B variant or intermediate NPD A/B) and 2) deficient enzymatic activity (as measured in peripheral leukocytes, cultured fibroblasts, lymphocytes, or DBS) or presence of 2 pathogenic SMPD1 mutations,
• The patient (or patient's legal guardian) must provide signed informed consent.

You may not qualify if…

• Patients suspected or diagnosed with infantile onset ASMD (ie, NPD A, with progressive developmental delay, or presence of any combination of R498L, L304P, and P333fs*52 genotypes, if available),
• Patients having received or receiving an investigational drug,
• Patients receiving any ASMD specific ERT,
• Patients with poor general condition that would not be able to undergo study assessments as per investigator's clinical judgment.
• The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Where it is running

• Investigational Site Number :8400002 — Atlanta, Georgia, United States
• Investigational Site Number :8400003 — The Bronx, New York, United States
• Investigational Site Number :8400001 — Valhalla, New York, United States
• Investigational Site Number :0320002 — CABA, Argentina
• Investigational Site Number :0320001 — Córdoba, Argentina
• Investigational Site Number :0560001 — Leuven, Belgium
• Investigational Site Number :0760001 — Porto Alegre, Rio Grande do Sul, Brazil
• Investigational Site Number :0760002 — São Paulo, Brazil
• Investigational Site Number :0760006 — São Paulo, Brazil
• Investigational Site Number :152001 — Santiago, Chile
• Investigational Site Number :152002 — Santiago, Chile
• Investigational Site Number :2030001 — Prague, Czechia
• Investigational Site Number :2500002 — Angers, France
• Investigational Site Number :2500003 — Paris, France
• Investigational Site Number :2500001 — Paris, France
• Investigational Site Number :2760002 — Giessen, Germany
• Investigational Site Number :2760005 — Mainz, Germany
• Investigational Site Number :380002 — Naples, Italy
• Investigational Site Number :380001 — Udine, Italy
• Investigational Site Number :6200001 — Porto, Portugal
• Investigational Site Number :6200002 — Porto, Portugal
• Investigational Site Number :6420001 — Timișoara, Romania
• Investigational Site Number :7240005 — Barcelona, Spain
• Investigational Site Number :7240001 — Madrid, Spain
• Investigational Site Number :7240004 — Seville, Spain

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.